Journal of Advanced Scientific Research

Available online through https://sciensage.info

ISSN

0976-9595

Review Article

Artificial Intelligence in Optimizing Formulations and Excipients: Revolutionizing Pharmaceutical Product Development

Amrendra Pratap Yadav[1*], Gurdeep Singh[2], Mukesh Kumar Singh[3], Anurag[4]

[1]Meerut Institute of Technology, Meerut, Uttar Pradesh, India.

[2]School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India.

[3]School of Pharmaceutical Science, Faculty of Pharmacy, IFTM University, Moradabad, Uttar Pradesh, India.

[4]Department of Pharmaceutical Technology, Meerut Institute of Engineering and Technology, Meerut, Uttar Pradesh, India.

*Corresponding author: amrendrapharma2009@gmail.com

Received: 17-07-2025; Accepted: 24-07-2025; Published: 31-07-2025

https://doi.org/10.55218/JASR.2025160702

ABSTRACT

The pharmaceutical industry is undergoing a paradigm shift with the integration of artificial intelligence (AI) technologies into research and development workflows. One of the most promising applications lies in the optimization of pharmaceutical formulations and excipient selection—a traditionally empirical and time-consuming process. AI, particularly machine learning and neural networks, has demonstrated immense potential in modeling complex formulation behaviors, predicting excipient compatibility, and streamlining the path to robust product development. By analyzing large datasets and identifying hidden patterns, AI tools facilitate rapid screening of excipients, forecasting of stability profiles, and real-time decision-making in formulation design. Furthermore, AI-driven models can complement or even surpass traditional statistical methods, such as the design of experiments, by enabling multi-objective optimization across various formulation parameters. Case studies involving tablets, lipid-based carriers, and nanotechnology-based systems illustrate the practical success of AI in enhancing formulation performance and reproducibility. Despite challenges such as data quality, algorithm transparency, and regulatory acceptance, the trajectory of AI adoption is accelerating, with its convergence with quality by design and process analytical technologies forming the foundation of next-generation pharmaceutical development. As AI technologies mature and become more interpretable and accessible, they are poised to redefine the role of formulation scientists and enable more personalized, efficient, and predictive formulation strategies. This manuscript explores the core principles, current applications, limitations, and future outlook of AI in pharmaceutical formulation science.

Keywords: Pharmaceutical formulation, Artificial intelligence, Excipients, Optimization, Machine learning, Quality by design.

INTRODUCTION

The development of safe, effective, and stable pharmaceutical formulations is a cornerstone of drug development. Formulation scientists have historically optimized drug-excipient combinations, process parameters, and dosage forms through empirical methods and trial-and-error experimentation. These traditional approaches frequently require a lot of time and resources, and they might not always produce the most reliable or effective results.[1] The incorporation of artificial intelligence (AI) and machine learning (ML) technologies into drug formulation and development pipelines has caused a revolutionary change in the pharmaceutical industry in recent years. These intelligent systems present new ways to improve predictive capabilities, speed up the formulation process, and more precisely optimize excipient selection and dosage form properties. [2,3]

Making educated decisions early in the formulation design stage is made possible by AI, especially ML algorithms, which can reveal intricate, non-linear relationships between a number of formulation variables and desired product attributes. AI algorithms are able to learn from past data, simulate novel situations, and forecast the best formulations under a range of circumstances, in contrast to traditional design of experiments (DoE), which investigates predetermined combinations. For instance, dissolution profiles, drug release kinetics, and excipient interactions have been impressively predicted using artificial neural networks (ANNs), random forests (RF), support vector machines (SVM), and deep learning (DL) models.[4-6]

The stability, bioavailability, manufacturing feasibility, and patient acceptability of pharmaceutical products are all significantly influenced by excipients, which are frequently regarded as inert. It is difficult to choose appropriate excipients and their concentrations from a constantly growing database. AI models can help by quickly vetting possible excipients and forecasting their suitability, effectiveness, and influence on the quality attributes of the finished product. For example, the solid-state stability and polymorphic transitions of active pharmaceutical ingredients (APIs) in combination

with different excipients have been predicted using ML tools.[3,7] Additionally, integrating AI supports the quality by design (QbD) principles, which use data-driven modeling to build an understanding of products and processes. AI lessens reliance on experimental trials, resulting in shorter development cycles and lower costs by modeling multiple formulation pathways and analyzing large datasets. Furthermore, automation and AI are increasingly being combined to enable real-time formulation design and control with the introduction of robotic systems and high-throughput screening.[8]

Even with these benefits, there are still difficulties. It is necessary to address issues such as the need for high-quality datasets, the interpretability of black-box models, and the regulatory ambiguity surrounding data generated by AI. However, the use of AI in pharmaceutical formulation signifies a change in approach from conventional to data-driven development methods. To illustrate the practical advancements in this domain, Table 1 highlights key studies that demonstrate the application of AI in optimizing pharmaceutical formulations and excipient selection, along with their respective methodologies.

Fundamentals of Machine Learning and Artificial Intelligence

AI is the term used to describe how computer systems can simulate human intelligence in order to carry out tasks like learning, reasoning, problem-solving, and decision-making. AI offers computational techniques in pharmaceutical sciences to manage intricate datasets and derive significant patterns that would otherwise be difficult to find using conventional techniques. A branch of artificial intelligence called ML uses statistical algorithms to let systems learn from data and get better without explicit programming.[19] To better understand how AI simulates human intelligence, Figure 1 presents the core technologies involved, such as cognitive computing and deep learning, which collectively empower AI systems to perceive, analyze, and respond to diverse data sources.

The three main categories of ML techniques are reinforcement learning, unsupervised learning, and supervised learning. To predict outcomes like drug solubility, stability, or bioavailability, supervised learning involves training the model on labeled datasets. Commonly used algorithms include ANNs, SVMs, decision trees, and linear regression. When modeling complex non-linear relationships between excipient combinations and drug release profiles, for instance, ANNs have demonstrated high predictive accuracy.[20,21]

When labeling is not available, unsupervised learning methods like principal component analysis (PCA) and k-means clustering are helpful for exploratory data analysis. These techniques can reduce dimensionality in high-throughput screening datasets, uncover hidden formulation trends, or classify excipients according to their functionality.

Although it hasn't been studied as much in the pharmacy field, reinforcement learning is becoming popular for real-time optimization tasks. In this approach, the system learns the best strategies through trial and error and receives feedback in the form of rewards or penalties.

DL, which models complex data structures using multiple layers of ANNs, is a significant development in ML. Image analysis, drug-target interaction prediction, and time-series pharmacokinetic data modeling have all benefited greatly from DL.[22]

AI makes it possible to replace empirical "trial-and-error" methods in pharmaceutical formulation with data-driven, predictive modeling. For example, ML algorithms can forecast how various excipients will affect a tablet's compressibility or disintegration time, facilitating quicker and more economical development cycles. Furthermore, AI models are flexible; as new data becomes available, they keep getting better, creating strong optimization frameworks for intricate formulations.

However, excellent, carefully selected datasets and a cooperative strategy between data scientists and domain experts are necessary for successful implementation. Building trust in AI applications in the

Table 1: Optimization of formulation by AI and machine learning methods

Objective of the work	*Formulation focus*	*AI / Method*	*References*
Predicting Oral Disintegrating Tablet Formulations by Neural Network Techniques	Oral Disintegrating Tablet disintegration time	ANN, DNN	[9]
Deep learning for *in-vitro* prediction of pharmaceutical formulations	Multiple dosage forms	Deep Neural Networks	[10]
In-silico formulation optimization and particle engineering of pharmaceutical products using a generative AI structure synthesis method	Tablet & implant design	Generative AI from images	[9]
VECT-GAN: A variationally encoded generative model for pharmaceutical science	Polymer design for mucoadhesion	Conditional GAN	[11]
Formulation AI: web-based AI platform for formulation prediction	Solid dispersions, liposomes, nanocrystals	Multiple ML models	[12]
Emerging AI technologies in solid dosage form development	Solid dosage forms	Expert systems + ML	[13]
AI-Directed formulation strategy design	Solid dispersions, controlled release	Interpretable ML methods	[14]
Smart Pharma TwinNet: AI-Driven Digital Twin for manufacturing	Manufacturing line optimization	Digital twins + IIoT	[15]
Digital twin of continuous direct compression line	Tablet continuous compression	Hybrid flowsheet modeling	[16]
Digital twin for adjuvant manufacturing (GMP environment)	Biopharmaceutical particle manufacture	Digital twin + ML	[17]
Assessment of pharmaceutical excipients via AI	Excipient evaluation	Data-intelligence algorithms	[18]



Fig. 1: Overview of how artificial intelligence works through key components such as cognitive computing, computer vision, machine learning, neural networks, deep learning, and natural language processing. [Created in https://BioRender.com]

pharmaceutical industry also requires transparency in model design, validation procedures, and regulatory compliance.

Formulation scientists are now equipped with tools that drastically shorten development timelines, enhance product performance, and foster innovation in cutting-edge drug delivery systems by utilizing AI and ML.

Challenges in Developing Conventional Formulations

The process of developing a traditional pharmaceutical formulation is difficult, time-consuming, and resource-intensive. Creating a stable, efficient, and patient-friendly dosage form entails choosing the right APIs, excipients, and manufacturing techniques. Formulation scientists have historically relied largely on empirical trial-and-error techniques, which are useful but inefficient and frequently fall short of exploring the entire design space of possible formulations.[23]

The high dimensionality and variability of formulation parameters are among the main obstacles. Depending on its physicochemical characteristics, such as solubility, stability, polymorphism, and hygroscopicity, each drug candidate may interact with excipients in a unique way. It is intrinsically challenging to predict these interactions without a mechanistic or data-driven approach. Additionally, despite being crucial to formulation success, excipient selection is frequently limited by regulatory constraints, formulation performance uncertainties, and a lack of compatibility data.[24-26]

There are also financial and time limitations. A new formulation's development cycle usually takes several months to years and involves scale-up trials, stability testing, and repeated batches. These procedures are costly and time-consuming, particularly when late-stage failures arise from unexpected stability problems or inadequate bioavailability.

Furthermore, two of the main issues in traditional development are process reproducibility and scale-up. Process variables like mixing speed, temperature, humidity, and equipment variations may cause formulations that were optimized at the lab scale to behave differently during pilot or commercial production. It takes a lot of validation and frequently re-optimization to ensure consistency across scales.[27]

The inability to make predictions is another drawback. The intricate relationships between formulation variables and product performance metrics (such as stability, bioavailability, and dissolution rate) are not naturally modeled or simulated by conventional methods. Longer development timelines and a higher chance of failure result from this limited capacity to make well-informed decisions early in the development process.[28] Figure 2 illustrates that AI and ML significantly overcome the limitations of the traditional method of pharmaceutical product development.

Lastly, the complexity of formulations keeps rising in response to the growing need for tailored and focused delivery systems, rendering conventional empirical approaches less suitable. Tools that can expedite and rationalize formulation decisions are becoming more and more necessary as pharmaceutical products move towards more intricate delivery platforms, like liposomes, nanoparticles, and implantable systems.[29]

These difficulties highlight how important it is to combine cutting-edge computational and data-driven methods in order to increase formulation efficiency, lower development costs, and enhance product performance and quality.

AI in Preformulation Research

Characterizing a drug's physicochemical characteristics in order to guide formulation strategies is known as preformulation, and it is an essential step in the development of pharmaceutical products. Potential formulation issues like poor solubility, instability, or drug-excipient incompatibility are identified at this stage.[30] Despite their effectiveness, traditional preformulation techniques can be expensive, time-consuming, and labor-intensive. An effective substitute that improves predictive accuracy, maximizes material utilization, and shortens development timelines is the incorporation of AI into preformulation studies.[31]



Fig. 2: The advantage of AI and machine learning over traditional methods in formulation development. (Created in https://BioRender.com)

Large datasets created during preformulation can be analyzed by AI technologies, particularly ML, DL, and computational modeling, to forecast a variety of properties like solubility, stability, permeability, and particle size distribution. In the early phases of formulation, when experimental data may be scarce, this predictive ability is especially helpful.[32] The use of AI predictive modeling in pharmaceutical development is demonstrated in Figure 3 in a number of areas, such as drug formulation, drug–exipient compatibility, improving drug solubility and bioavailability, and expediting the experimental design process.

Physicochemical Property Prediction

Using quantitative structure–activity relationship models and ML algorithms, one of the most significant uses of AI in preformulation is the prediction of physicochemical properties, including melting point, pKa, solubility, and logP.[33,34] These models establish connections between behavior and chemical structure by using molecular descriptors. For instance, aqueous solubility and stability of APIs have been successfully predicted with high accuracy using SVM, RF, and ANNs.[35]

AI can predict solubility outcomes for new chemical entities (NCEs) before they are validated experimentally by training models on large datasets from chemical databases like ChEMBL and PubChem. This helps choose suitable formulation strategies early in the pipeline and speeds up development.[36]

Analysis of Drug-Excipient Compatibility

Predicting drug-excipient interactions, a crucial component of preformulation, is another area where AI has demonstrated promise. Degradation, decreased effectiveness, or changed bioavailability can result from incompatibilities. Excipients can be categorized as compatible or incompatible by ML models trained on historical formulation data. These models take into account environmental factors like temperature and humidity as well as profiles of molecular interactions.[31] For example, by examining degradation kinetics under varied stress conditions, Bayesian networks and decision trees have been utilized to evaluate stability risks. Excipients that may catalyse oxidation or hydrolysis reactions can be identified by combining cheminformatics and AI, according to studies.[37,38]



Fig. 3: AI predictive modeling in drug formulation, drug-excipient compatibility, drug solubility, bioavailability, and increasing speed of experimental design. (Created in https://BioRender.com)

Solid-State Properties and Particle Engineering

Solid-state characterization, such as polymorphism, crystallinity, and hygroscopicity, is also included in preformulation and has a big impact on formulation performance. Using spectral data (e.g., XRPD, FTIR, Raman), AI algorithms, in particular convolutional neural networks, have been used to classify crystalline and amorphous forms. These methods enable greater control over polymorphic transitions and increase the solid-state screening's dependability.[39] Furthermore, using microscopy images, AI-enabled image analysis tools can analyze particle shape and surface morphology. High-throughput screening of particle characteristics essential to tabletability and flow behavior is made possible by this automation.[40]

Increasing the Speed of Experimental Design

Multiple formulation variables are traditionally studied using DoE approaches. However, by learning from previous experiments and simulating results under novel conditions, AI models can now either replace or augment DoE. In order to save resources and enhance decision-making, generative models and reinforcement learning can iteratively enhance predictions and suggest ideal experimental conditions.[3,41]

By improving prediction accuracy, decreasing empirical dependency, and optimizing resource utilization, AI integration into preformulation studies has the potential to revolutionize preformulation research. The combination of pharmaceutical sciences and AI-driven analytics represents a significant shift towards data-centric formulation development, even though the field is still developing. Future developments in federated learning and explainable AI could further democratize AI tools by increasing their interpretability and accessibility for both industry and academia.[42]

AI in the Selection and Optimization of Excipients

A key component of a successful pharmaceutical formulation is the selection and optimization of excipients, which have a significant impact on patient acceptability, drug stability, bioavailability, and manufacturing feasibility. Excipient selection has historically mainly depended on empirical approaches, iterative testing, and formulation scientists' knowledge. AI has been incorporated into formulation science, particularly in the logical selection and optimization of excipients, due to the growing complexity of contemporary dosage forms and the increasing need for development pathways that are both time- and cost-efficient.

Large, multidimensional datasets can be analyzed using AI, especially ML algorithms (Mol2vec + molecular descriptors + stacking), achieving high accuracy (AUC 0.93), which can reveal hidden patterns and non-linear relationships that control excipients' performance. Under a variety of process and environmental circumstances, these models are able to forecast the interactions between excipients and the API as well as other formulation elements. Such predictive abilities could speed up the creation of reliable formulations and significantly lessen the need for thorough wet-lab testing.[43]

Among AI methods, supervised learning models like ANNs, decision trees, and SVM are frequently used to forecast the characteristics and behavior of excipients. To predict the ideal concentrations of binders, disintegrants, or surfactants based on target disintegration time, compressibility, and dissolution rate, for instance, ANN models can be trained on historical formulation datasets. To identify outliers in excipients compatibility profiles or to categorize excipients into functional groups, unsupervised learning techniques like PCA and clustering are also used.[44,45]

Recent research has shown how useful AI is for forecasting excipient-drug compatibility based on thermodynamic parameters and molecular descriptors. For example, a study by Dukić *et al.* achieved accuracy rates of over 90% by using ML algorithms to evaluate compatibility between APIs and widely used excipients based on parameters like solubility, polarity, and hydrogen bonding potential.[46] The formulation design process is streamlined by the early detection of excipients that could jeopardize drug stability or efficacy, made possible by this predictive modeling technique.

Furthermore, excipient attributes can be optimized within specified design spaces by successfully integrating AI with QbD principles. Researchers can create surrogate models that mimic the effects of excipient variability on critical quality attributes (CQAs) by fusing ML algorithms with DoE data. These models guarantee a more reliable formulation process by facilitating real-time risk assessment and decision-making.[31,47]

Using generative models, like variation autoencoders and generative adversarial networks (GANs), to create unique excipient combinations with customized functions is an increasingly innovative field. These models, though still in the early stages of development, point to a time when AI will be able to help with both selection and the conceptualization of novel excipients with programmable performance profiles. To sum up, AI-assisted excipient optimization and selection is a revolutionary development in drug formulation. AI facilitates a data-driven, predictive approach that enhances experimental methods by utilizing computational power and pattern recognition. It is projected that these tools will become essential to the development of next-generation pharmaceuticals as regulatory confidence in AI-driven methodologies grows.[48]

AI Models for Formulation Optimization

Numerous factors, such as the physicochemical characteristics of the drug, interactions between excipients, and process parameters, are involved in the development of pharmaceutical formulations. Historically, this has depended on statistical methods like DoE or empirical methods like trial-and-error. However, when the formulation space becomes extremely complex and multidimensional, these approaches frequently fail. Robust formulation optimization is made possible by AI, especially ML, which offers a potent substitute by enabling pattern recognition, predictive modeling, and data-driven decision-making.

The optimization of drug formulations has extensively investigated ML algorithms, including RF, SVMs, ANNs, and genetic algorithms (GAs). These models can analyze big datasets to find intricate non-linear relationships between formulation inputs (like excipient type and concentration, process variables) and outputs (like stability, bioavailability, and dissolution rate), which are frequently hard to capture with traditional tools.

ANNs, which draw inspiration from the human brain, are especially good at simulating multidimensional and non-linear relationships. ANNs have been applied to pharmaceutical formulation to forecast disintegration time, drug release profile, and encapsulation efficiency. By accurately forecasting *in-vitro* drug release, for example, an ANN-based model was successfully used to optimize sustained-release matrix tablets.[49]

SVMs are another ML technique that can be used for both regression and classification tasks. They are useful for differentiating between optimal and non-optimal formulation conditions because of their strength in creating hyperplanes in high-dimensional space. SVMs outperformed regression-based models in predicting particle size and zeta potential in a study that optimized nanoparticle formulation.[49,50]

The ensemble learning technique random forest (RF) effectively manages missing data and offers resilience against overfitting. RF has been used to forecast the best combinations for desired quality attributes and rank the significance of formulation variables. For instance, solid dispersion systems were modelled using RF, which precisely determined the excipient ratios that optimized solubility and dissolution rate.[51]

Genetic algorithms (GAs) are widely used for optimization tasks in addition to predictive models. In order to iteratively find the ideal formulation conditions, these bio-inspired algorithms mimic evolutionary processes. In order to create hybrid systems that can both predict and optimize formulation outcomes, GAs are frequently combined with ANNs or other ML models.[52]

Additionally, formulators can simultaneously take into account several quality attributes, like stability, hardness, and bioavailability, to create the best possible formulation design by combining AI with multi-objective optimization techniques. In QbD frameworks, where a design space must be established to guarantee constant product quality, this is especially helpful.

There are still issues with data accessibility, model interpretability, and regulatory acceptance in spite of these developments. However, it is anticipated that the use of AI models in formulation development will become more commonplace as pharmaceutical databases expand and explainable AI techniques advance.

Applications and Case Studies

Formulation design, excipient selection, and process optimization have all been profoundly impacted by the rapid evolution of AI in pharmaceutical formulation science from theoretical models to real-world case studies. These uses range from traditional dosage forms like pills and capsules to cutting-edge delivery methods like lipid-based carriers and nanoparticles. This section focuses on illustrative case studies that show how AI technologies have been used to effectively optimize pharmaceutical formulations.

Optimizing Tablet Formulation with AI Support

One traditional application of AI that has shown great promise in balancing drug release, stability, and manufacturability is tablet formulation. In one important study, the hardness and disintegration time of ibuprofen-containing tablets were predicted using an ANN. The model was trained on experimental data using different concentrations of lactose and microcrystalline cellulose as excipients.

In comparison to conventional DoE methods, the ANN model demonstrated a high degree of predictive accuracy and reduced the number of experimental trials required by more than 60%.[53]

SVM were used in a different study to forecast the dissolution profiles of diclofenac sodium sustained-release formulations. The SVM model guided the ideal excipient concentration for intended release kinetics by precisely controlling formulation parameters through the analysis of data on compression force, binder levels, and polymer concentration.[54]

Machine Learning in Formulations Based on Nanoparticles

Particle size, polydispersity index (PDI), and encapsulation efficiency must all be tightly controlled for nanocarriers like solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs). In this regard, AI models like random forest (RF) and genetic algorithms (GA) have proven effective.

A random forest model was used in a study by Agrawal *et al*. (2021) to forecast the ideal lipid and surfactant concentrations for NLCs loaded with curcumin. Rapid screening of formulations with improved bioavailability was made possible by the model's accurate predictions of particle size and encapsulation efficiency. Similar to this, chitosan nanoparticle preparation conditions have been optimized using GA-ANN hybrid models, which has led to high encapsulation efficiency with fewer experimental iterations.[55]

Drug Delivery Systems Based on Lipids (LBDDS)

Because of the intricate interactions between the lipid phase, surfactant concentration, and drug solubility, lipid-based systems in particular, self-emulsifying drug delivery systems or SEDDS present formulation challenges. ANNs were used in a study by Saini *et al*. (2024) to optimize the composition of a SEDDS formulation of olmesartan medoxomil. The model predicted the drug loading capacity and self-emulsification time, and optimized formulations demonstrated better oral bioavailability and dissolution.[56]

Artificial Intelligence in Amorphous Solid Dispersions (ASDs)

Drugs that are poorly soluble in water can be made more soluble by using amorphous solid dispersions, but it can be difficult to predict the ideal polymer matrix and processing parameters. To forecast the glass transition temperature (Tg) and miscibility of drug-polymer systems, researchers used ML models. For example, based on experimental conditions and chemical structure descriptors, an XGBoost model correctly predicted the Tg of several ASD systems, allowing for a quicker selection of polymer matrices.[57,58]

Combining Automation and Robotics

AI has been incorporated into automated formulation platforms to facilitate closed-loop formulation design, going beyond model prediction. One such system used robotic arms that were controlled by AI algorithms to prepare a large number of formulations simultaneously. Real-time disintegration, drug release, and physical property analyses were performed on these, and the data were used to continuously retrain the model, establishing a feedback loop for ongoing improvement.[59,60] In personalized medicine, where AI-guided systems can quickly create customized doses based on patient-specific pharmacokinetic profiles and therapeutic windows, this integration has proven especially helpful.

AI-Powered Continuous Manufacturing and Hot-Melt Extrusion

A crucial method in continuous pharmaceutical manufacturing, hot-melt extrusion (HME) is complicated by a number of interrelated factors, including feed rate, temperature, and screw speed. To optimize formulation and process parameters, AI models have been utilized to forecast the extrusion torque, melt viscosity, and uniformity of drug distribution. In one study, the formulation of HME-based tablets with poorly soluble medications was optimized using ANN models. Batch-to-batch consistency and material waste were greatly enhanced by the AI model.[61,62]

Combining Robotics and High-Throughput

Pharmaceutical formulation development has changed as a result of the combination of robotics, high-throughput experimentation (HTE), and AI. Automated platforms that can generate and analyze large datasets in a fraction of the time are gradually replacing traditional formulation methods, which are frequently constrained by time, cost, and human variability. While AI algorithms concurrently analyse intricate datasets to find the best formulation combinations, these systems allow for the quick screening of formulation variables, such as excipient type, concentration, and process parameters.

Researchers can create hundreds to thousands of formulation variations under consistent, repeatable conditions using high-throughput robotic platforms. These automated systems improve data integrity, decrease human error, and increase productivity. These platforms support iterative optimization cycles when used in conjunction with AI models, such as ML and DL. Through a closed-loop design-make-test-analyze (DMTA) cycle, the AI component continuously learns from experimental outputs, improves prediction models, and suggests additional experimental conditions.[60]

For instance, humanoid robotic systems with intelligent decision-making skills can perform tasks like mixing, material dispensing, and real-time data acquisition on their own, allowing for round-the-clock operation. These developments are especially helpful when screening formulations for intricate drug delivery systems where multi-variable optimization is essential, like solid dispersions, sustained-release matrices, or nanoparticles.[63-65]

The integration of reinforcement learning and Bayesian optimization into robotic systems for the exploration of large formulation spaces is a noteworthy application. Compared to conventional DoE methods, such combinations have shown the ability to achieve optimal product performance (e.g., disintegration time, dissolution rate, and stability) with a significantly reduced number of experimental runs.

Additionally, the integration of AI and robotics promotes the concepts of process analytical technology (PAT) and QbD, enabling improved comprehension and management of critical process parameters (CPPs) and CQAs.[66]

High-throughput robotic platforms and AI work together to speed up the formulation process and promote innovation by making it possible to find new excipient combinations and processing conditions that might not be obvious through traditional experimentation.

Regulatory and Quality Considerations

Significant improvements are brought about by the incorporation of artificial AI into pharmaceutical formulation development, but there are also significant obstacles in the form of regulatory acceptance, quality assurance, and compliance. Authorities such as the U.S. European Medicines Agency (EMA), the Food and Drug Administration (FDA), and others have acknowledged the revolutionary potential of AI and are actively working to develop frameworks to guarantee its safe and efficient use.[67,68]

Data integrity, model transparency, and reproducibility are three major regulatory concerns with AI-driven formulation. Conventional formulation strategies are easier to audit because they are transparent and comparatively linear. On the other hand, AI algorithms, especially DL and neural networks, frequently act as "black boxes," with opaque internal decision-making processes. Regulatory review is made more difficult by this lack of explainability, especially for CQAs and CPPs that are necessary to guarantee the safety and effectiveness of the product (ICH Q8-R2, Q9, Q10).

Regulators support "explainable AI" (XAI) models that produce interpretable results in order to address this. Similar to the good ML practice (GMLP) guidelines recently put forth by the FDA and other international organizations, careful documentation of algorithm design, training data sets, validation outcomes, and performance metrics is required.

Furthermore, integrating AI should be in line with the principles of QbD, where AI tools can help with risk assessments, design space establishment, and formulation behavior prediction. Evidence of model robustness, such as sensitivity analysis, external validation, and lifecycle monitoring plans, should be included in regulatory submissions involving AI-optimized products. In order to ensure compliance, real-time model updates that are utilized in continuous manufacturing also need version control and audit trails.

Digital twins and model-informed drug development (MIDD), in which AI models model formulation processes *in-silico* prior to actual bench testing, are two new approaches. Despite their potential, these models need to show a high level of accuracy and dependability in order to be approved by regulators.[69]

Lastly, data privacy regulations (such as GDPR and HIPAA) must be followed by pharmacovigilance and post-marketing surveillance employing AI-driven models, particularly when patient-specific data is utilized to guide formulation personalization.

Overall, although AI provides a groundbreaking toolkit for pharmaceutical formulation, regulatory adoption necessitates adherence to the principles of reproducibility, validation, transparency, and ongoing monitoring. Successful product approval and market translation depend on early regulatory agency engagement and adherence to changing AI guidelines.

Challenges and Limitations

AI in pharmaceutical sciences is becoming more and more popular, but a number of obstacles and restrictions prevent it from being seamlessly incorporated into formulation development. These difficulties range from data-related problems to interpretability and regulatory issues, particularly when AI is used for excipient selection and optimization.

The absence of comprehensive, standardized, and high-quality datasets is one of the main drawbacks. Data on pharmaceutical formulations are frequently dispersed throughout internal R&D reports, published literature, and proprietary databases, and they might not adhere to standard data reporting guidelines. AI models, which rely on sizable, clean, and structured datasets for training and validation, are limited in their efficacy by this data heterogeneity.[70]

The "black-box" nature of many AI models, particularly DL networks, is another significant obstacle. Although these models are highly accurate at predicting outcomes, their decision-making process is frequently opaque. Pharmaceutical scientists and regulatory agencies find it challenging to trust AI-generated formulation decisions due to their lack of interpretability if they do not comprehend the reasoning behind them.[71] Although explainable AI (XAI) techniques are being developed to address this problem, their uptake is still in its early stages.

Another issue with AI models is their generalisability. When applied to new medications or dosage forms, AI systems trained on particular drug-excipient combinations or formulation types might not function well. Formulation sciences are intricate and impacted by manufacturing, physicochemical, and biological factors that might not be sufficiently represented in small datasets.

Another logistical challenge is integration with current pharmaceutical workflows. Conventional formulation development mainly depends on expert intuition and experimental methods. Since there are no guarantees of returns, many institutions are reluctant to invest in retraining staff, redesigning workflows, and modifying legacy systems in order to integrate AI into these processes.[72]

Furthermore, it's still unclear if regulations will accept formulations aided by AI. Regulatory agencies like the FDA and EMA are still developing guidelines for AI and ML in drug development. Regulatory confidence in AI outputs is being hampered by a lack of standardized validation processes as well as issues with data provenance, model retraining, and reproducibility.[73]

Lastly, there are growing ethical concerns about algorithmic bias, data privacy, and ownership of formulations produced by AI. These problems could restrict AI's long-term potential in pharmaceutical formulation science in the absence of clear frameworks.

Future Prospects

It is anticipated that the application of AI to pharmaceutical formulation science will advance significantly, influencing a future in which drug delivery and design become more patient-centered, accurate, and swift. The creation of digital twins, or virtual copies of actual formulation systems, is among the most exciting developments. These models eliminate the need for lengthy experimental trials by simulating the stability and performance of formulations under a variety of conditions in real time. In continuous manufacturing settings, where AI-enabled real-time feedback loops can dynamically optimize formulation variables, digital twins are being investigated more and more.[74]

The application of generative AI to the development of innovative formulation techniques is another revolutionary possibility. In order to suggest completely novel combinations and delivery methods, generative models such as transformer-based architectures and generative adversarial networks (GANs) are being trained on sizable

datasets of excipients, drug compounds, and effective formulations. This strategy could result in the identification of novel excipient uses or co-processing methods that improve the stability and bioavailability of difficult medications.

Furthermore, AI-powered personalized formulation development is becoming a cutting-edge use case. AI systems can be used to customize formulations that fit each patient's unique therapeutic response profile by combining pharmacogenomic data with physiological parameters unique to each patient. Off-the-shelf formulations frequently fall short in oncology, paediatrics, and rare diseases, where such customization may be especially helpful.

There is also a lot of promise in the convergence of AI with continuous manufacturing and PAT. PAT systems can incorporate predictive AI models to identify deviations, forecast batch failures, and instantly adjust process parameters. In addition to improving manufacturing efficiency, this degree of automation guarantees adherence to QbD guidelines.

Another avenue for the future is the creation of AI-enabled robotic labs, where humanoid robotic systems use real-time data and optimization feedback to develop formulations on their own. It is anticipated that these systems will speed up high-throughput screening of formulations and excipients, cutting down on development time and expense.[16]

Despite these opportunities, it is important to carefully manage data privacy issues, regulatory gaps, and ethical concerns. To guarantee safety, openness, and reproducibility, regulatory agencies are anticipated to create rules especially for AI-assisted formulation tools.[75]

In summary, AI in pharmaceutical formulation is set to undergo a swift and intelligent transformation in the future. Formulation science will be redefined by its integration with cutting-edge technologies like digital twins, robotics, and personalized medicine frameworks, which will make it more flexible, effective, and patient-centered.

CONCLUSION

A revolutionary change in the conception, development, and optimization of pharmaceutical products is represented by the incorporation of AI into pharmaceutical formulation design. AI-driven predictive modeling, ML algorithms, and data-centric design strategies are complementing and, in some cases, redefining traditional formulation approaches, which frequently depend on extensive trial-and-error methods.

AI makes it possible to quickly screen and choose excipients, predict formulation stability, and identify important material properties and process parameters by utilizing big datasets and sophisticated algorithms. Crucially, these tools enable formulators to investigate large experimental areas that would be otherwise impractical with traditional techniques, which ultimately reduces development times and improves product design accuracy.

Furthermore, the combination of AI and QbD frameworks is starting to change how regulations are implemented. As long as AI is applied transparently and validated, regulatory bodies are beginning to recognize its potential to improve patient safety and product quality. Customized dosage forms can be created based on patient-specific information, pharmacogenomic profiles, and therapeutic requirements thanks to the use of AI in preformulation and formulation.

Notwithstanding these developments, difficulties still exist. Barriers to wider industrial adoption include data quality, interpretability of algorithms, and the "black-box" nature of many ML models. Furthermore, the regulatory acceptance of AI models in pharmaceutical settings is limited by the absence of standardized protocols for their validation. To close these gaps, cooperation between data scientists, pharmaceutical scientists, and regulatory stakeholders is crucial.

Future developments in AI-powered formulation development are probably going to move towards closed-loop, autonomous systems that incorporate digital twins, robotics, and real-time analytics. In addition to increasing productivity, these developments will make it possible for ongoing process enhancements and flexible manufacturing techniques.

In conclusion, AI has enormous potential for pharmaceutical formulation science, especially for excipient optimization. It has the potential to usher in a new era of clever, effective, and patient-centered drug development with responsible application and interdisciplinary cooperation.

REFERENCES

1. Bannigan P, Aldeghi M, Bao Z, Häse F, Aspuru-Guzik A, Allen C. Machine learning directed drug formulation development. Adv Drug Deliv Rev. 2021 Aug;175:113806.
2. Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug Discov Today. 2019 Mar;24(3):773–80.
3. Ali KA, Mohin S, Mondal P, Goswami S, Ghosh S, Choudhuri S. Influence of artificial intelligence in modern pharmaceutical formulation and drug development. Futur J Pharm Sci. 2024 Mar 29;10(1):53.
4. Galata DL, Könyves Z, Nagy B, Novák M, Mészáros LA, Szabó E, *et al*. Real-time release testing of dissolution based on surrogate models developed by machine learning algorithms using NIR spectra, compression force and particle size distribution as input data. Int J Pharm. 2021 Mar;597:120338.
5. Benkő E, Ilič IG, Kristó K, Regdon G, Csóka I, Pintye-Hódi K, *et al*. Predicting Drug Release Rate of Implantable Matrices and Better Understanding of the Underlying Mechanisms through Experimental Design and Artificial Neural Network-Based Modelling. Pharmaceutics. 2022 Jan 19;14(2):228.
6. Momeni M, Afkanpour M, Rakhshani S, Mehrabian A, Tabesh H. A prediction model based on artificial intelligence techniques for disintegration time and hardness of fast disintegrating tablets in pre-formulation tests. BMC Med Inform Decis Mak. 2024 Mar 27;24(1):88.
7. Serrano DR, Luciano FC, Anaya BJ, Ongoren B, Kara A, Molina G, *et al*. Artificial Intelligence (AI) Applications in Drug Discovery and Drug Delivery: Revolutionizing Personalized Medicine. Pharmaceutics. 2024 Oct 14;16(10):1328.
8. Bekhit AA, Nasralla SN, El-Agroudy EJ, Hamouda N, El-Fattah AA, Bekhit SA, *et al*. Investigation of the anti-inflammatory and analgesic activities of promising pyrazole derivative. European Journal of Pharmaceutical Sciences. 2022 Jan;168:106080.
9. Hornick T, Mao C, Koynov A, Yawman P, Thool P, Salish K, *et al*. In silico formulation optimization and particle engineering of pharmaceutical products using a generative artificial intelligence

structure synthesis method. Nat Commun. 2024 Nov 7;15(1):9622.
10. Yang Y, Ye Z, Su Y, Zhao Q, Li X, Ouyang D. Deep learning for in vitro prediction of pharmaceutical formulations. Acta Pharm Sin B. 2019 Jan;9(1):177–85.
11. Abdalla Y, Taub M, Hilton E, Akkaraju P, Milanovic A, Orlu M, *et al*. VECT-GAN: A variationally encoded generative model for overcoming data scarcity in pharmaceutical science. 2025 Jan 17;
12. Dong J, Wu Z, Xu H, Ouyang D. FormulationAI: a novel web-based platform for drug formulation design driven by artificial intelligence. Brief Bioinform. 2023 Nov 22;25(1).
13. Jiang J, Ma X, Ouyang D, Williams RO. Emerging Artificial Intelligence (AI) Technologies Used in the Development of Solid Dosage Forms. Pharmaceutics. 2022 Oct 22;14(11):2257.
14. Wang N, Dong J, Ouyang D. AI-directed formulation strategy design initiates rational drug development. Journal of Controlled Release. 2025 Feb;378:619–36.
15. Malik A, Rajaguru P, Azzawi R. Smart Manufacturing with Artificial Intelligence and Digital Twin: A Brief Review. In: 2022 8th International Conference on Information Technology Trends (ITT). IEEE; 2022. p. 177–82.
16. Moreno-Benito M, Lee KT, Kaydanov D, Verrier HM, Blackwood DO, Doshi P. Digital twin of a continuous direct compression line for drug product and process design using a hybrid flowsheet modelling approach. Int J Pharm. 2022 Nov;628:122336.
17. Phalak P, Tomba E, Jehoulet P, Kapitan-Gnimdu A, Soladana PM, Vagaggini L, *et al*. Digital Twin Implementation for Manufacturing of Adjuvants. Processes. 2023 Jun 3;11(6):1717.
18. Kumar A, Gupta G Das, Raikwar S. Artificial Intelligence Technologies used for the Assessment of Pharmaceutical Excipients. Curr Pharm Des. 2024 Feb;30(6):407–9.
19. Shah P, Kendall F, Khozin S, Goosen R, Hu J, Laramie J, *et al*. Artificial intelligence and machine learning in clinical development: a translational perspective. NPJ Digit Med. 2019 Jul 26;2(1):69.
20. Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug Discov Today. 2019 Mar;24(3):773–80.
21. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, *et al*. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019 Jun 11;18(6):463–77.
22. Singh S, Numan A, Maddiboyina B, Arora S, Riadi Y, Md S, *et al*. The emerging role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer. Drug Discov Today. 2021 Jul;26(7):1721–7.
23. Ezike TC, Okpala US, Onoja UL, Nwike CP, Ezeako EC, Okpara OJ, *et al*. Advances in drug delivery systems, challenges and future directions. Heliyon. 2023 Jun;9(6):e17488.
24. Kesisoglou F, Panmai S, Wu Y. Nanosizing — Oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev. 2007 Jul;59(7):631–44.
25. Raw A. Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs). Adv Drug Deliv Rev. 2004 Feb 23;56(3):397–414.
26. Serajuddin ATM. Salt formation to improve drug solubility. Adv Drug Deliv Rev. 2007 Jul;59(7):603–16.
27. Bai JPF, Burckart GJ, Mulberg AE. Literature Review of Gastrointestinal Physiology in the Elderly, in Pediatric Patients, and in Patients with Gastrointestinal Diseases. J Pharm Sci. 2016 Feb;105(2):476–83.
28. Kang MS, Lee SY, Kim KS, Han DW. State of the Art Biocompatible Gold Nanoparticles for Cancer Theragnosis. Pharmaceutics. 2020 Jul 25;12(8):701.
29. Yang ZY, He JH, Lu AP, Hou TJ, Cao DS. Frequent hitters: nuisance artifacts in high-throughput screening. Drug Discov Today. 2020 Apr;25(4):657–67.
30. Damiati SA. Digital Pharmaceutical Sciences. AAPS PharmSciTech. 2020 Jul 26;21(6):206.
31. Vora LK, Gholap AD, Jetha K, Thakur RRS, Solanki HK, Chavda VP. Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design. Pharmaceutics. 2023 Jul 10;15(7):1916.
32. Singh L, Tiwari RK, Verma S, Sharma V. The Future of Artificial Intelligence in Pharmaceutical Product Formulation. Drug Deliv Lett. 2019 Oct 31;9(4):277–85.
33. Xing L, Glen RC. Novel Methods for the prediction of logP, pKa, and logD. J Chem Inf Comput Sci. 2002 Jul 1;42(4):796–805.
34. Fink T, Reymond JL. Virtual Exploration of the Chemical Universe up to 11 Atoms of C, N, O, F: Assembly of 26.4 Million Structures (110.9 Million Stereoisomers) and Analysis for New Ring Systems, Stereochemistry, Physicochemical Properties, Compound Classes, and Drug Discovery. J Chem Inf Model. 2007 Mar 1;47(2):342–53.
35. Wen H, Närvänen A, Jokivarsi K, Poutiainen P, Xu W, Lehto VP. A robust approach to make inorganic nanovectors biotraceable. Int J Pharm. 2022 Aug;624:122040.
36. Lusci A, Pollastri G, Baldi P. Deep Architectures and Deep Learning in Chemoinformatics: The Prediction of Aqueous Solubility for Drug-Like Molecules. J Chem Inf Model. 2013 Jul 22;53(7):1563–75.
37. Cheng F, Zhao Z. Machine learning-based prediction of drug–drug interactions by integrating drug phenotypic, therapeutic, chemical, and genomic properties. Journal of the American Medical Informatics Association. 2014 Oct;21(e2):e278–86.
38. Ceschan NE, Rosas MD, Olivera ME, Dugour AV, Figueroa JM, Bucalá V, *et al*. Development of a Carrier-Free Dry Powder Ofloxacin Formulation With Enhanced Aerosolization Properties. J Pharm Sci. 2020 Sep;109(9):2787–97.
39. Bugay DE. Characterization of the solid-state: spectroscopic techniques. Adv Drug Deliv Rev. 2001 May;48(1):43–65.
40. Rajesh MV, Elumalai K. The transformative power of artificial intelligence in pharmaceutical manufacturing: Enhancing efficiency, product quality, and safety. Journal of Holistic Integrative Pharmacy. 2025 Jun;6(2):125–35.
41. Korshunova M, Huang N, Capuzzi S, Radchenko DS, Savych O, Moroz YS, *et al*. Generative and reinforcement learning approaches for the automated de novo design of bioactive compounds. Commun Chem. 2022 Oct 18;5(1):129.
42. Suriyaamporn P, Pamornpathomkul B, Patrojanasophon P, Ngawhirunpat T, Rojanarata T, Opanasopit P. The Artificial Intelligence-Powered New Era in Pharmaceutical Research and Development: A Review. AAPS PharmSciTech. 2024 Aug 15;25(6):188.
43. Hang NT, Long NT, Duy ND, Chien NN, Van Phuong N. Towards safer and efficient formulations: Machine learning approaches to predict drug-excipient compatibility. Int J Pharm. 2024 Mar;653:123884.
44. Hamid JU, Gupta S. Development and validation of a system for the prediction of excipient-excipient incompatibility using machine learning tools. Pharmaspire. 2022;14(01):18–27.
45. Patel S, Patel M, Kulkarni M, Patel MS. DE-INTERACT: A machine-learning-based predictive tool for the drug-excipient interaction study during product development—Validation through paracetamol and vanillin as a case study. Int J Pharm. 2023 Apr;637:122839.
46. Ono T, Yonemochi E. Evaluation of the physical properties of dry surface-modified ibuprofen using a powder rheometer (FT4) and analysis of the influence of pharmaceutical additives on improvement of the powder flowability. Int J Pharm. 2020 Apr;579:119165.
47. Jain N, Kaul S, Triveni, Kaith A, Sinha A, Mathur T, *et al*. 8 QbD and

artificial intelligence in nanoparticulate drug delivery systems: recent advances. In: Computational Drug Delivery. De Gruyter; 2024. p. 163–82.
48. Prykhodko O, Johansson SV, Kotsias PC, Arús-Pous J, Bjerrum EJ, Engkvist O, *et al*. A de novo molecular generation method using latent vector based generative adversarial network. J Cheminform. 2019 Dec 3;11(1):74.
49. Muneer R, Hashmet MR, Pourafshary P, Shakeel M. Unlocking the Power of Artificial Intelligence: Accurate Zeta Potential Prediction Using Machine Learning. Nanomaterials. 2023 Mar 29;13(7):1209.
50. Öztürk K, Kaplan M, Çalış S. Effects of nanoparticle size, shape, and zeta potential on drug delivery. Int J Pharm. 2024 Dec;666:124799.
51. Noorain, Srivastava V, Parveen B, Parveen R. Artificial Intelligence in Drug Formulation and Development: Applications and Future Prospects. Curr Drug Metab. 2023 Sep;24(9):622–34.
52. Rao RV, Savsani VJ. Mechanical Design Optimization Using Advanced Optimization Techniques. London: Springer London; 2012.
53. Mura P, Orlandini S, Cirri M, Maestrelli F, Mennini N, Casella G, *et al*. A preliminary study for the development and optimization by experimental design of an in vitro method for prediction of drug buccal absorption. Int J Pharm. 2018 Aug;547(1–2):530–6.
54. Das PJ, Preuss C, Mazumder B. Artificial Neural Network as Helping Tool for Drug Formulation and Drug Administration Strategies. In: Artificial Neural Network for Drug Design, Delivery and Disposition. Elsevier; 2016. p. 263–76.
55. El-Naggar NEA, Dalal SR, Zweil AM, Eltarahony M. Artificial intelligence-based optimization for chitosan nanoparticles biosynthesis, characterization and in-vitro assessment of its anti-biofilm potentiality. Sci Rep. 2023 Mar 16;13(1):4401.
56. Andor M, Temereancă C, Sbârcea L, Ledeți A, Man DE, Mornoș C, *et al*. Host–Guest Interaction Study of Olmesartan Medoxomil with β-Cyclodextrin Derivatives. Molecules. 2024 May 8;29(10):2209.
57. Jiang J, Lu A, Ma X, Ouyang D, Williams RO. The applications of machine learning to predict the forming of chemically stable amorphous solid dispersions prepared by hot-melt extrusion. Int J Pharm X. 2023 Dec;5:100164.
58. Han R, Xiong H, Ye Z, Yang Y, Huang T, Jing Q, *et al*. Predicting physical stability of solid dispersions by machine learning techniques. Journal of Controlled Release. 2019 Oct;311–312:16–25.
59. Tom G, Schmid SP, Baird SG, Cao Y, Darvish K, Hao H, *et al*. Self-Driving Laboratories for Chemistry and Materials Science. Chem Rev. 2024 Aug 28;124(16):9633–732.
60. Bannigan P, Hickman RJ, Aspuru-Guzik A, Allen C. The Dawn of a New Pharmaceutical Epoch: Can AI and Robotics Reshape Drug Formulation? Adv Healthc Mater. 2024 Nov 18;13(29).
61. Munir N, Nugent M, Whitaker D, McAfee M. Machine Learning for Process Monitoring and Control of Hot-Melt Extrusion: Current State of the Art and Future Directions. Pharmaceutics. 2021 Sep 9;13(9):1432.
62. Munir N, de Lima T, Nugent M, McAfee M. In-line NIR coupled with machine learning to predict mechanical properties and dissolution profile of PLA-Aspirin. Functional Composite Materials. 2024 Oct 8;5(1):14.
63. Han C, Dong X, Zhang W, Huang X, Gong L, Su C. Intelligent Systems for Inorganic Nanomaterial Synthesis. Nanomaterials. 2025 Apr 21;15(8):631.
64. Cao L, Russo D, Lapkin AA. Automated robotic platforms in design and development of formulations. AIChE Journal. 2021 May 3;67(5).
65. Jena GK, Patra CN, Jammula S, Rana R, Chand S. Artificial Intelligence and Machine Learning Implemented Drug Delivery Systems: A Paradigm Shift in the Pharmaceutical Industry. J BioX Res. 2024 Jan 23;7.
66. Gisperg F, Klausser R, Elshazly M, Kopp J, Brichtová EP, Spadiut O. Bayesian Optimization in Bioprocess Engineering—Where Do We Stand Today? Biotechnol Bioeng. 2025 Jun 5;122(6):1313–25.
67. Pasas-Farmer S, Jain R. From discovery to delivery: Governance of AI in the pharmaceutical industry. Green Analytical Chemistry. 2025 Jun;13:100268.
68. Niazi SK. Regulatory Perspectives for AI/ML Implementation in Pharmaceutical GMP Environments. Pharmaceuticals. 2025 Jun 16;18(6):901.
69. Davidopoulou C, Ouranidis A. Pharma 4.0-Artificially Intelligent Digital Twins for Solidified Nanosuspensions. Pharmaceutics. 2022 Oct 3;14(10):2113.
70. Kant S, Deepika, Roy S. Artificial intelligence in drug discovery and development: transforming challenges into opportunities. Discover Pharmaceutical Sciences. 2025 Jun 2;1(1):7.
71. Malheiro V, Santos B, Figueiras A, Mascarenhas-Melo F. The Potential of Artificial Intelligence in Pharmaceutical Innovation: From Drug Discovery to Clinical Trials. Pharmaceuticals. 2025 May 25;18(6):788.
72. Mansur MA. Artificial Intelligence in Drug Discovery Towards Strategic Applications Challenges and Implementation Frameworks for Accelerated Pharmaceutical Innovation. European Journal of Artificial Intelligence and Machine Learning. 2025 May 31;4(3):16–23.
73. Kant S, Deepika, Roy S. Artificial intelligence in drug discovery and development: transforming challenges into opportunities. Discover Pharmaceutical Sciences. 2025 Jun 2;1(1):7.
74. Sajadieh SMM, Noh S Do. From Simulation to Autonomy: Reviews of the Integration of Artificial Intelligence and Digital Twins. International Journal of Precision Engineering and Manufacturing-Green Technology. 2025 May 3;
75. Phalak P, Tomba E, Jehoulet P, Kapitan-Gnimdu A, Soladana PM, Vagaggini L, *et al*. Digital Twin Implementation for Manufacturing of Adjuvants. Processes. 2023 Jun 3;11(6):1717.

HOW TO CITE THIS ARTICLE: Yadav AP, Singh G, Singh MK, Anurag. Artificial Intelligence in Optimizing Formulations and Excipients: Revolutionizing Pharmaceutical Product Development. *J Adv Sci Res*. 2025;16(07): 9-18 **DOI:** 10.55218/JASR.2025160702